Hepatitis C reinfection after sustained virological response
| Autor: | Jan Kristian Damås, Håvard Midgard, John H.-O. Pettersson, Zbigniew Konopski, Kathrine Stene-Johansen, Hege Kileng, Benedikte Bjøro, Arild Mæland, Lars Normann Karlsen, Jetmund O. Ringstad, Olav Dalgard, Dagny Haug Dorenberg, Lars Heggelund, Jørn Paulsen, Per Sandvei |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Sustained Virologic Response Denmark Population Hepacivirus Antiviral Agents 03 medical and health sciences 0302 clinical medicine Recurrence Risk Factors Internal medicine medicine Odds Ratio Humans 030212 general & internal medicine education Retrospective Studies Sweden education.field_of_study Hepatology business.industry Norway Incidence (epidemiology) Incidence Hazard ratio virus diseases Retrospective cohort study Hepatitis C Odds ratio Hepatitis C Chronic Middle Aged Viral Load medicine.disease Immunology RNA Viral 030211 gastroenterology & hepatology Female business Viral hepatitis Viral load Follow-Up Studies |
| Zdroj: | Journal of hepatology. 64(5) |
| ISSN: | 1600-0641 |
| Popis: | Background & Aims On-going risk behaviour can lead to hepatitis C virus (HCV) reinfection following successful treatment. We aimed to assess the incidence of persistent HCV reinfection in a population of people who inject drugs (PWID) who had achieved sustained virological response (SVR) seven years earlier. Methods In 2004–2006 we conducted a multicentre treatment trial comprising HCV genotype 2 or 3 patients in Sweden, Norway and Denmark (NORTH-C). Six months of abstinence from injecting drug use (IDU) was required before treatment. All Norwegian patients who had obtained SVR (n=161) were eligible for participation in this long-term follow-up study assessing virological and behavioural characteristics. Results Follow-up data were available in 138 of 161 (86%) individuals. Persistent reinfection was identified in 10 of 94 (11%) individuals with a history of IDU prior to treatment (incidence rate 1.7/100 person-years (PY); 95% CI 0.8–3.1) and in 10 of 37 (27%) individuals who had relapsed to IDU after treatment (incidence rate 4.9/100 PY; 95% CI 2.3–8.9). Although relapse to IDU perfectly predicted reinfection, no baseline factor was associated with reinfection. Relapse to IDU was associated with age vs. ⩾40years) at treatment (adjusted odds ratio [aOR] 7.03; 95% CI 1.78–27.8) and low education level (aOR 3.64; 95% CI 1.44–9.18). Conclusions Over time, persistent HCV reinfection was common among individuals who had relapsed to IDU after treatment. Reinfection should be systematically addressed and prevented when providing HCV care for PWID. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect